logo
ŌURA Redefines Metabolic Health Tracking with Two New AI-Driven Features: Meals and Glucose

ŌURA Redefines Metabolic Health Tracking with Two New AI-Driven Features: Meals and Glucose

Business Wire06-05-2025

SAN FRANCISCO--(BUSINESS WIRE)--ŌURA, maker of the world's leading smart ring, today announced a significant expansion of its product experience through the introduction of two new metabolic health features, Meals and Glucose. With these new product capabilities, ŌURA takes a holistic, AI-driven approach to metabolic health by combining meal insights with glucose data from Stelo by Dexcom, the first FDA-cleared glucose biosensor available without a prescription in the United States, directly in the Oura App. These new features empower members with personalized insights and actionable guidance and are a major milestone in ŌURA's journey toward becoming a fully integrated health solution.
'Our product roadmap for this year is built on a robust investment in AI-forward offerings that enable a deeper understanding of the dynamic interplay of key health factors,' said Holly Shelton, chief product officer at ŌURA. 'The addition of nutrition-focused features to our product experience was a natural next step, especially considering how personal diet—and its impact on health—can be. Our bodies all process food in different ways, which is why we're leveraging a unique combination of ŌURA's extensive biometric tracking, generative AI, and Stelo glucose data to address a critical need for more individualized and accessible metabolic health solutions. By integrating nutrition information with activity, stress, and sleep, we're empowering members with a deeper understanding of how their daily habits influence their wellbeing.'
Metabolic health plays a critical role in overall vitality, affecting everything from energy levels and mood to long-term disease risk. While conditions such as Type 2 diabetes, hypertension, and obesity are on the rise—with over 800 million people globally living with obesity and nearly half a billion adults living with prediabetes—metabolic dysfunction can impact individuals even in the absence of a formal diagnosis. Poor metabolic health has been linked to increased risk of cardiovascular disease, stroke, kidney disease, and more, and may also contribute to everyday symptoms such as fatigue, brain fog, and decreased physical performance. As a result, supporting metabolic health is essential not only for managing disease but also for optimizing how individuals feel and function in daily life.
Proactive management through lifestyle changes can dramatically reduce these risks and symptoms; however, metabolic processes are intricate, and factors like genetics, hormones, and environmental influences can play a role. This complexity can make it difficult to pinpoint the most effective strategies for optimizing metabolic health.
Through its new Meals and Glucose features, in addition to its existing feature set spanning sleep, stress, activity, heart health, and more, ŌURA provides a comprehensive and integrated metabolic experience, setting it apart from existing offerings and directly responding to the growing demand for more personalized and holistic metabolic management tools.
Meals
After months of testing and supportive feedback in Oura Labs, Oura's innovation hub, Meals has transitioned to a permanent feature in the Oura App. By simply taking a picture, members can quickly log their food and see how effectively their meals and snacks fuel them through AI-powered food recognition and comprehensive nutrition analysis. Unlike traditional meal tracking apps that emphasize calorie counts, Meals focuses on macronutrients and is designed to help members better understand how their dietary choices affect their health, empowering them to develop sustainable habits aligned with their goals.
When members take or upload photos of their meals in the Oura App, ŌURA analyzes the dish to provide an immediate overview of its contents. Once analyzed, Oura Advisor provides guidance and feedback on nutritional choices so members can learn how to build satiating, nutrient-dense meals to avoid energy slumps and cravings.
Meals also includes a Nutrition Breakdown component, which categorizes key nutritional elements like protein, fiber, processing level, added sugars, total fats, and total carbs to provide an informational, at-a-glance summary. Oura's guidance avoids penalizing food choices, instead presenting non-judgmental insights that help members make informed choices based on their health objectives, whether that's improving energy levels, maintaining metabolic health, or enhancing dietary balance.
Glucose
Through ŌURA's strategic partnership and integration with Dexcom, a global leader in glucose biosensing, Oura members can now purchase a Stelo directly from ouraring.com to receive 24/7 glucose insights and gain a better understanding of their metabolic health. Stelo, a small biosensor worn on the back of the upper arm, leverages Dexcom's most accurate¹ glucose sensing technology and reveals how lifestyle factors can affect glucose.
Prior to Stelo's launch in August 2024, glucose biosensors were only available with a prescription, and often involved significant out-of-pocket costs for those without insurance coverage. Since receiving FDA-clearance, Stelo has expanded access to this technology, giving more people valuable information about their health. Members who integrate Stelo with Oura will see their daily glucose readings in the context of their meals, sleep, stress, and activity through a new Glucose feature in the Oura App.
'Personalized guidance and insights are essential for helping people understand how their lifestyle choices affect their body, while also encouraging them to make informed health decisions that can improve their overall quality of life,' said Jake Leach, executive vice president and chief operating officer at Dexcom. 'By integrating with ŌURA, we're bringing the first glucose biosensor and smart ring integration to the market, providing a one-of-a-kind and personalized metabolic health experience that allows users to better understand the link between activity, sleep, stress, nutrition, and their glucose. Through this partnership, we're once again redefining the wearable technology category in the pursuit of empowering people to take control of their health.'
Within the Glucose feature in the Oura App, contextual graphs and insights from Oura Advisor help members understand the interplay between meals, stress, daily movement, tags, and glucose so members can learn lifestyle habits that help them maintain or achieve optimal glucose levels. The feature will also provide a new key metric, 'Time Above Range,' which tracks how long glucose stays above the target range and provides an AI-powered analysis of glucose trends for that day.
'Our approach to metabolic health and glucose monitoring is uniquely ŌURA,' said Shyamal Patel, senior vice president of science at ŌURA. 'Meal-induced glucose spikes can vary significantly due to factors like sleep, stress, exercise, and meal timing, which is why it's important to approach metabolic health holistically rather than focusing exclusively on diet. Instead of avoiding specific foods based on one spike, we encourage members to observe patterns, experiment with habits, and discover what helps them maintain better glucose balance over time. With this approach, members can maintain a healthy relationship with food while building long-term habits that support metabolic health.'
AI-Powered Health Insights
Meals and Glucose join the suite of features supported by ŌURA's AI-powered health coach, Oura Advisor. Oura Advisor is a holistic LLM designed to give Oura members personalized, contextual, and empathetic guidance. In addition to integrating with various features in the Oura App, Oura Advisor can answer general health questions and pull in charts of a member's Sleep, Readiness, or Activity data to guide and support them in making changes that align with their health goals.
'AI has been part of the Oura experience since its inception, powering our core features and driving the personalized experience our members have come to know and love,' said Shelton. 'With the launch of Meals, Glucose, and Oura Advisor—and the strategic integration of AI across all three—we're taking a pivotal step forward in connecting the dots to deliver the most personal and holistic health platform available. This launch is a significant milestone in our goal to continuously innovate and give members agency over their health.'
Pricing and Availability
At launch, Meals and Glucose will be available on iOS and Android for Oura members based in the United States, with plans to launch Meals internationally later this year. Oura Advisor currently provides the most personalized responses about Oura data related to Sleep, Activity, Readiness, and Resilience. Oura Advisor intelligence will be released across additional Oura features in the coming months.
New and existing Oura members will be able to purchase Stelo directly from ouraring.com for $99. Each Stelo order includes two sensors for a wear-time of up to 15 days each. Stelo can be purchased bundled with or without a ring and will be available in the United States only.
Stelo is cleared by the FDA for adults not on insulin who are 18 or older * in the United States interested in tracking their glucose, and for people with Type 2 diabetes not using insulin or those with prediabetes. Both Oura Ring and Stelo are eligible for purchase with FSA/HSA funds.
To learn more about Oura's metabolic health features, visit here.
Stelo Safety Information: For full information on risks and benefits, visit stelo.com.
1 Dexcom, Data on File, 2024.
* Adults 18 years or older not on insulin.
About ŌURA:
ŌURA delivers personalized health data, insights, and daily guidance with Oura Ring, the leading smart ring that helps you live healthier, longer. Guided by a mission of changing the healthcare paradigm from sick care to preventative health, ŌURA makes wellness and recovery a daily practice through sleep, activity, readiness, stress, resilience, women's health, and heart health. Millions of Oura members around the world use Oura Ring as a personalized health companion that meets them where they are.
ŌURA is building the most scientifically validated wearable; the lightweight and comfortable Oura Ring is validated against medical gold standards and driven by continuous monitoring of 50+ individual health and wellness biometrics and insights. Thousands of teams, research organizations, and concierge medical practices manage the health of their populations with ŌURA, and its ecosystem includes 800+ partners across women's health, metabolic health, fitness, behavioral health, and more. ŌURA was founded in 2013 in Finland and has offices in Oulu, Helsinki, San Francisco, and San Diego. For more information, please visit http://ouraring.com/ and connect with ŌURA on Instagram, LinkedIn, and TikTok.
Oura Ring is not a medical device and is not intended to diagnose, treat, cure, monitor, or prevent medical conditions/illnesses.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SpikImm and SATT Conectus Sign a Definitive Licensing Agreement for Prophylactic Treatment Against the BK Virus, to Prevent Severe Complications in Transplant Patients
SpikImm and SATT Conectus Sign a Definitive Licensing Agreement for Prophylactic Treatment Against the BK Virus, to Prevent Severe Complications in Transplant Patients

Business Wire

time3 hours ago

  • Business Wire

SpikImm and SATT Conectus Sign a Definitive Licensing Agreement for Prophylactic Treatment Against the BK Virus, to Prevent Severe Complications in Transplant Patients

PARIS--(BUSINESS WIRE)-- SpikImm, a clinical-stage biotechnology company founded in 2021 by Truffle Capital in collaboration with Institut Pasteur and dedicated to the development of monoclonal antibodies to prevent viral infections in immunocompromised patients, today announced the signature with SATT Conectus of an exclusive collaboration and worldwide license agreement for potent monoclonal antibodies targeting the BK virus. These monoclonal antibodies were developed through the project HuMABK led by Pr. Samira FAFI-KREMER, Director of the Institut de Virologie de Strasbourg and Pr. Pascal POIGNARD, Head of the "Antibodies and Infectious Diseases" research team at the Institut de Biologie Structurale of Grenoble. This agreement reinforces SpikImm's portfolio and expertise for the prophylactic treatment of viral infections in immunocompromised patients. Since the option agreement signed in 2024, SpikImm has already made progress in its preclinical work, and has successfully completed the development of the cell line for GMP manufacturing. The aim is to carry out the first in human studies by 2026. BK virus (BKV) infects most individuals early in life and typically remains latent without causing disease. However, under immunosuppressive treatment, in particular in transplant patients, BKV can reactivate and replicate in the urinary tract, leading to potentially serious complications. In kidney transplant recipients; BKV reactivation may result in graft loss and increase the risk of bladder cancer. In addition, BKV is responsible for severe hemorrhagic cystitis in bone marrow graft recipients. No BKV-specific antiviral therapies or vaccines are currently available. Therefore, there is an urgent medical need for the development of novel anti-BKV prophylactic treatments. Thanks to the work of Pr. FAFI-KREMER, Head of renowned Institut de Virologie of Strasbourg (U1109 University of Strasbourg / Inserm, Strasbourg University Hospitals) and her team, the key role of anti-BKV neutralizing antibodies for protection against BKV infection and associated diseases was uncovered. Building upon these insights, Pr. FAFI-KREMER and Pr. POIGNARD joined forces to develop anti-BKV neutralizing monoclonal antibodies under the HuMABK project, funded by ANR and SATT Conectus. The expertise in antibody discovery of Pr. POIGNARD and collaborators of the Institut de Biologie Structurale (CEA/CNRS / University of Grenoble Alpes / UMR 5075) enabled the successful isolation of broad and potent anti-BKV neutralizing human monoclonal antibodies. These monoclonal antibodies represent promising candidates for future clinical development as potential best-in-class options. SpikImm and SATT Conectus today announced the signature of a worldwide exclusive licensing agreement for the anti-BKV monoclonal antibodies. These antibodies are engineered to potentially provide effective, long-lasting protection against the serious complications associated with BKV, offering a prophylactic solution for transplant recipients. With its partners Institut Pasteur and LFB, SpikImm has already demonstrated its expertise in rapidly bringing from discovery to clinical trials two anti-SARS COV2 monoclonal antibodies within twelve months, creating a unique platform for the accelerated discovery and development of monoclonal antibodies to the benefit of patients. SpikImm is focused on the accelerated development of long-acting monoclonal antibodies to protect immunocompromised patients from several viral infections, including SARS-CoV-2 and BKV. Pr. FAFI-KREMER, PharmD, PhD, University Professor-Hospital Practitioner, Head of Institut de Virologie de Strasbourg (U1109 University of Strasbourg / Inserm, Strasbourg University Hospitals) and Pr. POIGNARD, M.D., Ph.D, University Professor-Hospital Practitioner (University of Grenoble Alpes - CHU Grenoble-Alpes), Head of "Antibodies and Infectious Diseases" research team at the Institut de Biologie Structurale of Grenoble (CEA-CNRS-UGA Mixed Research Unit 5075) comment: "Reactivation of the BK virus in patients receiving kidney transplant, bone marrow or stem cell grafts has potential serious consequences and represents a growing medical challenge. The HuMABK monoclonal antibodies discovered by Grenoble's Institut de Biologie Structurale in collaboration with Strasbourg's Institut de Virologie are remarkably effective in neutralizing this virus and represent a promising antiviral strategy. We are convinced that the collaboration with SpikImm will ensure a rapid clinical development. Specifically, we anticipate that the monoclonal antibodies will significantly enhance patient care, notably by preserving kidney transplants, and promoting favorable outcomes in bone marrow recipients. ' James PHILLIPS, MD, CEO of SpikImm, comments: "We are delighted to sign this agreement for these highly promising monoclonal antibodies against the BK virus. SpikImm will be able to draw on the exceptional quality of the research team, as well as the strong support of SATT Conectus, to advance this project and bring new hope to the vulnerable immunocompromised patients.' Philippe POULETTY, MD, chairman of SpikImm comments " SpikImm's mission is to protect immunocompromised patients from severe viral diseases. These potent anti-BKV monoclonal antibodies will reinforce SpikImm's pipeline to offer broad protection against several severe infections. SpikImm embodies Truffle Capital approach: to actively create and grow companies with outstanding science to address major unmet needs.' Emmanuel POTEAUX, Chairman and CEO of SATT Conectus, highlights: " The signing of this technology licence marks an outstanding scientific collaboration between two leading researchers working at the heart of two regions of academic excellence, Alsace and Grenoble. The combined financial investment from the ANR and SATT Conectus made it possible to obtain and validate robust preclinical results, paving the way for clinical development. We are delighted that SpikImm is taking over to continue the development of this major health innovation for patients.' The HuMABK project is supported by: About SpikImm SpikImm is a French clinical-stage biotech founded by Truffle Capital in collaboration with Institut Pasteur in 2021 to develop human monoclonal antibodies for the prevention of severe infectious diseases affecting immunocompromised patients. SpikImm's lead candidates SPK001 and SPK002, have been originally developed in the laboratory of Humoral Immunology (Institut Pasteur & Inserm U1222) headed by Dr Hugo MOUQUET, as long-acting monoclonal antibodies for the prevention of COVID-19 in immunocompromised patients. SpikImm is currently expanding its portfolio of monoclonal antibodies against severe viral infections, through collaborations with prestigious academic research teams, starting with BKV infection. More information: About Truffle Capital Founded in 2001, Truffle Capital is an independent European Venture Capital firm specializing in Life Sciences (MedTech and BioTech) and disruptive technologies in the I.T. sector (FinTech and InsurTech). Truffle Capital's mission is to support the creation and development of young innovative companies capable of becoming tomorrow's leaders. Managed by Dr. Philippe Pouletty and Bernard-Louis Roques, co-founders and CEOs, Truffle Capital has €500 million in assets under management. It has raised more than €1.2 billion since its creation and has supported more than 70 companies in the digital technology and life sciences sectors. More information: — Twitter: @trufflecapital About SATT Conectus SATT* Conectus is the main entry point for business partners and companies to access all the innovations and capabilities from public research in Alsace, one of the top ranked territories for the excellence of research in France. Thanks to its investment fund, SATT CONECTUS offers advanced, applicative technologies whose proofs of concept have been established, and ready to industrialize. Therefore investors will have access to groundbreaking startups built around those breakthrough yet matured technologies. Another type of collaboration allows companies to co-develop high potential innovative projects with public research, in order to tailor them to their specific needs. * technology transfer acceleration organization More information: About the Institut de Virologie de Strasbourg The Institut de Virologie de Strasbourg, headed by Pr. FAFI KREMER is affiliated with the Faculty of Medicine of the University of Strasbourg, the Strasbourg University Hospitals and the Inserm Unit U1109, LabEx TRANSPLANTEX. For more than 10 years, his research has focused on the study of virus-host interaction in the pathogenesis of polyomaviruses (BK virus)-associated diseases in immunocompromised individuals, particularly transplant patients. The central aim is to ultimately identify accurate and personalized biomarkers and to develop urgently needed, preventive and therapeutic antiviral strategies. About the Institut de Biologie Structurale (IBS) The IBS, a mixed research unit CEA-CNRS-Université Grenoble Alpes (UMR 5075), hosts the "Antibodies and Infectious Diseases" research team headed by Pr. POIGNARD, specialized in the study of humoral responses to viral, bacterial and parasitic infections. After playing a key role in the discovery of broadly neutralizing antibodies against HIV, P Poignard has extended his interest to other viruses, such as the BK virus, but also to bacteria and parasites. In particular, his team focuses on the development of innovative strategies for the discovery of human monoclonal antibodies to develop new therapeutic approaches and help vaccine design.

Stallergenes Greer Showcases Developments in Respiratory and Food Allergy Care at EAACI 2025
Stallergenes Greer Showcases Developments in Respiratory and Food Allergy Care at EAACI 2025

Business Wire

time4 hours ago

  • Business Wire

Stallergenes Greer Showcases Developments in Respiratory and Food Allergy Care at EAACI 2025

BAAR, Switzerland--(BUSINESS WIRE)--Stallergenes Greer, a global leader in allergy therapeutics, will present insightful scientific developments at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, Glasgow (United Kingdom) June 13-16. The company will present 25 posters and host two scientific symposia during which six world-leading experts will share their insight on respiratory and food allergy: 'Breath of change: redefining respiratory allergy care with remission in sight': with environmental change impacting respiratory allergies, a new approach to disease management is necessary. Clinical remission is emerging as a relevant treatment goal for Type 2 allergies and allergen immunotherapy (AIT) has the potential to cater to this approach. ' Myth busting in peanut allergy: separating fact from fiction ': misconceptions about food allergy management may influence treatment decisions, thus underscoring the vital role of patient-clinician communication. ' We are enthusiastic to share how Stallergenes Greer is bolstering its impact in the field of respiratory and food allergy. Our research findings highlighted at the symposia, as well as through scientific posters and presentations, reflect our determination to deliver innovative allergen immunotherapy solutions that offer sustained benefits for patients worldwide,' stated Dr Elena Rizova, Chief Medical Officer, Stallergenes Greer. ' Our portfolio offers a broad range of proven treatment solutions designed to provide long-lasting relief for patients with allergies across a spectrum of conditions ranging from allergic rhinitis and asthma to food allergy.' The presentation of the posters will showcase Stallergenes Greer's latest research efforts and reaffirm its commitment to advancing personalised allergy care for the benefit of patients and healthcare professionals. Topics include patient benefits with AIT and its potential for clinical remission, new data from the recent real-world study VORAN on 300 IR House Dust Mite (HDM) SLIT tablet, PDAH (defatted powder of Arachis Hypogaea L., semen [peanut]) allergen consistency compared to supermarket peanut products, and prevention of food-induced anaphylaxis in children, including toddlers. SYMPOSIA AND POSTERS COMPANY SPONSORED SYMPOSIUM (June 13, 13:30–14:30 – Room: Meeting Academy M1) "Breath of change: redefining respiratory allergy care with remission in sight" Chair: Prof. Adnan Custovic, United Kingdom - 'Climate, pollution, and the escalating allergy burden: time for a treatment paradigm shift' Speaker: Prof. Guillaume Lezmi, France - 'From symptom control to disease remission: a new vision for allergic asthma' Speaker: Prof. Oliver Pfaar, Germany - 'Allergen immunotherapy: unlocking sustainable relief for allergic rhinitis' Speaker: Prof. Randolph Brehler, Germany COMPANY SPONSORED SYMPOSIUM (June 14, 14:30–15:00 – Room: Boisdale) ' Myth busting in peanut allergy: separating fact from fiction ' Speakers: Dr Aikaterini Anagnostou, United States of America, and Dr Pablo Rodríguez del Río, Spain POSTERS Among the topics covered by the 25 posters, specific findings will be presented and discussed in depth: Recent findings highlight the potential of Stallergenes Greer immunotherapies to provide sustained symptom relief and reduce reliance on corticosteroids even after treatment cessation, aligning with the concept of clinical remission on and off treatment. Evidence from VORAN, the first European real-world data generation study with 300 IR HDM SLIT tablet, supports the safety profile and effectiveness of this treatment in HDM-induced allergic rhinitis with or without controlled asthma in more than 700 adults and adolescents, with over 80% having improved their symptoms and sleep and almost 2/3 stopping nasal corticosteroid use. These findings are further supported by the PRACTIS study, where the benefits of SLIT-liquid met expectations in approximately 90% of patients with allergic rhino conjunctivitis and/or asthma. Furthermore, Stallergenes Greer recently conducted studies showing that its peanut allergy treatment, PDAH, is consistent and offers a positive risk-benefit ratio. Unlike common peanut products found in supermarkets, which can vary in protein and allergen levels, PDAH shows consistency across batches. The research also points to an opportunity to help children from 1 year, when their immune systems may be more adaptable. In clinical studies, the treatment helped reduce the risk of accidental allergic reactions and showed a solid safety record, especially in toddlers. ABOUT THE EAACI CONGRESS The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956. EAACI is dedicated to improving the health of people affected by allergic diseases. With more than 16,000 members from 125 countries and over 50 National Allergy Societies, EAACI is the primary source of expertise in Europe and worldwide for all aspects of allergy. Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. For more information, visit

Samsung Bioepis Presents Long-Term Safety Data of EPYSQLI™ (Eculizumab) in PNH at the European Hematology Association (EHA) Congress 2025
Samsung Bioepis Presents Long-Term Safety Data of EPYSQLI™ (Eculizumab) in PNH at the European Hematology Association (EHA) Congress 2025

Business Wire

time4 hours ago

  • Business Wire

Samsung Bioepis Presents Long-Term Safety Data of EPYSQLI™ (Eculizumab) in PNH at the European Hematology Association (EHA) Congress 2025

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. ('Samsung Bioepis') today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a biosimilar to Soliris 1, in paroxysmal nocturnal hemoglobinuria (PNH) at the European Hematology Association (EHA) Congress 2025 held at Milan, Italy from June 12 to 15. Long-term follow-up of EPYSQLI's Phase 3 study showed consistency of safety data between the initial 52-week period and the extended treatment period up to 158 weeks Share EPYSQLI was approved by the European Commission (EC) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in May 2023 and March 2024, respectively 2. The study assessed the long-term safety of EPYSQLI in PNH patients by evaluating the consistency of safety outcomes, particularly serious adverse events (SAEs) between the initial 52-week Phase 3 study period and the extended treatment (ET) period, spanning from 52 weeks to up to 158 weeks. The same maintenance dose of 900 mg EPYSQLI was administered every 2 weeks. A total of 46 patients from the Phase 3 study received ET. During ET, seven patients (15.2%) experienced a total of 14 SAEs with no occurrence of fatal cases, and all patients fully recovered without permanently discontinuing the treatment. The exposure-adjusted event rate (EAER) was comparable between initial 52-week period and ET period (EAER were 0.13 and 0.17, respectively), and there was no statistically difference between initial 52-week and ET period in EAER (p-value = 0.76). The study is consistent with the findings of the Phase 3 study with no newly identified safety signals and no fatal cases occurred throughout the entire treatment period with all SAEs resolving completely. Details of the abstract are as follows 3: Abstract title: Long-Term Safety of SB12 in Paroxysmal Nocturnal Hemoglobinuria: Up to 2-year Extension Treatment Safety Data Abstract number: PB2811 Type: Publication Only Session title: Bone marrow failure syndromes incl. PNH – Clinical Author(s): Jun Ho Jang, Siook Baek, Yumin Baek, Jinah Jung, Ciprian Tomuleasa, Hanna Oliynyk, Theerin Lanamtieng, Soo Min Lim Besides approval by the EC, EPYSQLI is also approved by the U.S. Food and Drug Administration (FDA) and Korea's Ministry of Food and Drug Safety (MFDS) as a biosimilar to Soliris. In countries where EPYSQLI is approved and available, EPYSQLI may not be prescribed and/or dispensed for its unapproved other indications for which Soliris is approved. About EPYSQLI (Eculizumab Biosimilar) in the European Union (EU) EPYSQLI is indicated in adults and children for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). EPYSQLI is not approved for and should not be used for the treatment of generalised myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). EPYSQLI must be administered by a healthcare professional and under the supervision of a physician experienced in the management of patients with hematological disorders or renal disorders. EPYSQLI EU Important Safety Information The EU Summary of Product Characteristics for EPYSQLI includes the following Special warning and Precautions: Meningococcal Infection Due to its mechanism of action, the use of eculizumab increases the patient's susceptibility to meningococcal infection (Neisseria meningitidis). Meningococcal disease due to any serogroup may occur. To reduce the risk of infection, all patients must be vaccinated at least 2 weeks prior to receiving eculizumab unless the risk of delaying eculizumab therapy outweighs the risks of developing a meningococcal infection. Patients who initiate eculizumab treatment less than 2 weeks after receiving a tetravalent meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Vaccines against serogroups A, C, Y, W 135 are recommended in preventing the commonly pathogenic meningococcal serogroups. Vaccine against serogroup B where available is also recommended. Patients must receive vaccination according to current national vaccination guidelines for vaccination use. Vaccination may further activate complement. As a result, patients with complement-mediated diseases, including PNH and aHUS, may experience increased signs and symptoms of their underlying disease, such as haemolysis (PNH) or TMA (aHUS). Therefore, patients should be closely monitored for disease symptoms after recommended vaccination. Vaccination may not be sufficient to prevent meningococcal infection. Consideration should be given to official guidance on the appropriate use of antibacterial agents. Cases of serious or fatal meningococcal infections have been reported in eculizumab-treated patients. Sepsis is a common presentation of meningococcal infections in patients treated with eculizumab. All patients should be monitored for early signs of meningococcal infection, evaluated immediately if infection is suspected, and treated with appropriate antibiotics if necessary. Patients should be informed of these signs and symptoms and steps taken to seek medical care immediately. Other Systemic Infections Patients may have increased susceptibility to other type of serious infections, especially with Neisseria and encapsulated bacteria. Infusion Reactions Administration of eculizumab may result in infusion reactions or immunogenicity that could cause allergic or hypersensitivity reactions (including anaphylaxis). Eculizumab administration should be interrupted in all patients experiencing severe infusion reactions and appropriate medical therapy administered. Anticoagulant therapy Treatment with eculizumab should not alter anticoagulant management. PNH Laboratory Monitoring PNH patients should be monitored for signs and symptoms of intravascular haemolysis, including serum lactate dehydrogenase (LDH) levels, and may require dose adjustment within the recommended 14±2 day dosing schedule during the maintenance phase (up to every 12 days). aHUS Laboratory Monitoring aHUS patients receiving eculizumab therapy should be monitored for thrombotic microangiopathy by measuring platelet counts, serum LDH and serum creatinine, and may require dose adjustment within the recommended 14±2 day dosing schedule during the maintenance phase (up to every 12 days). Treatment Discontinuation for PNH If patients discontinue treatment with eculizumab they should be closely monitored for signs and symptoms of serious intravascular haemolysis. Treatment Discontinuation for aHUS If aHUS patients discontinue treatment with eculizumab, they should be monitored closely for signs and symptoms of severe thrombotic microangiopathy complications. The most common adverse reaction observed with eculizumab treatment in clinical trials was headache, (occurred mostly in the initial phase of dosing), and the most serious adverse reaction was found to be meningococcal infection. Refer to the Summary of Product Characteristics for EPYSQLI's full safety information.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store